Interactions between medications employed in treating benign prostatic hyperplasia and food − A short review

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 1141-1145

  Paśko, Paweł ^a   Rodacki, Tomasz ^a   Domagała Rodacka, Renata ^a   Owczarek, Danuta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

5 reductase inhibitors; Alcohol; Alpha 1 adrenergic receptor antagonists; Benign prostatic hyperplasia; Grapefruit; Interaction drugs food

Indexed keywords

ALCOHOL; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; ANTINEOPLASTIC AGENT;

CITRUS FRUIT; DRUG EFFICACY; DRUG SAFETY; FOOD DRUG INTERACTION; FRUIT JUICE; GRAPEFRUIT JUICE; HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SYSTEMATIC REVIEW; DRUG INTERACTION; FOOD; MALE; PROSTATIC HYPERPLASIA;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; FOOD; HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 84989323077     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.08.021     Document Type: Review

References (29)

1. [1] Praveen, R., Benign prostatic hyperplasia: updated review. Int. Res. J. Pharm. 4 (2013), 45–51.
2. [2] Hollingsworth, J.M., Wilt, T.J., Lower urinary tract symptoms in men. BMJ, 349, 2014, g4474.
3. [3] Kapoor, A., Benign prostatic hyperplasia (BPH) management in the primary care setting. Can. J. Urol. 19 (2012), 10–17.
4. [4] Edwards, J.L., Diagnosis and management of benign prostatic hyperplasia. Am. Fam. Physician 77 (2008), 1403–1410.
5. [5] Rittmaster, R.S., 5α-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract. Res. Clin. Endocrinol. Metab. 22 (2008), 389–402.
6. [6] Bailey, D.G., Dresser, G., Arnold, J.M.O., Grapefruit-medication interactions: forbidden fruit or avoidable consequences?. CMAJ 185 (2013), 309–316.
7. [7] Mazi-Kotwal, N., Seshadri, M., Drug Interactions with grapefruit juice. BJMP, 5, 2012, a538.
8. [8] Vuichoud, C., Loughlin, K.R., Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can. J. Urol. 22 (2015), 1–6.
9. [9] Heuberger, R., Polypharmacy and food–drug interactions among older persons: a review. J. Nutr. Gerontol. Geriatr. 31 (2012), 325–403.
10. [10] Wilde, M.I., Fitton, A., McTavish, D., Alfuzosin. Drugs 45 (1993), 410–429.
11. [11] Uroxatral (Sanofi-aventis U.S. LLC): Prescribing information.
12. [12] Deepalakshmi, M., Arun, K.P., Ahuja, S., Grapefruit and medications may be a deadly mix- an overview. J. Pharm. BioSci. 3 (2014), 80–84.
13. [13] Kawano, Y., Abe, H., Kojima, S., Takishita, S., Omae, T., Interaction of alcohol and an α1-blocker on ambulatory blood pressure in patients with essential hypertension. Am. J. Hypertens. 13 (2000), 307–312.
14. [14] Chung, M., Vashi, V., Puente, J., Sweeney, M., Meredith, P., Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br. J. Clin. Pharmacol. 48 (1999), 678–687.
15. [15] X.L. Cardura (Pfizer Inc.): Prescribing information.
16. [16] Conway, E.L., McNeil, J.J., Hurley, J., Jackman, G.P., Krum, H., Howes, L.G., Louis, W.J., The effects of food on the oral bioavailability of doxazosin in hypertensive subjects. Drug Invest. 6 (1993), 90–95.
17. [17] Montorsi, F., Profile of silodosin. Eur. Urol. 9 (2010), 491–495.
18. [18] Rapaflo (Actavis Specialty Pharmaceuticals Co): Product monograph.
19. [19] Yoshida, M., Homma, Y., Kawabe, K., Silodosin, a novel selective α1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Exp. Opin. Investig. Drugs 16 (2007), 1955–1965.
20. [20] Flomax (Boehringer Ingelheim Pharmaceuticals, Inc): Prescribing information.
21. [21] Michel, M.C., Korstanje, C., Krauwinkel, W., Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. Eur. Urol. Suppl. 4 (2005), 9–14.
22. ®). Eur. Urol. Suppl. 4 (2005), 15–24.
23. [23] Chapple, C.R., Chartier-Kastler, E., Pharmacokinetic profile of tamsulosin OCAS. BJU Int. 98 (2006), 9–12.
24. [24] Takanaga, H., Ohnishi, A., Murakami, H., Matsuo, H., Higuchi, S., Urae, A., Irie, S., Furuie, H., Matsukuma, K., Kimura, M., Kawano, K., Orii, Y., Tanaka, T., Sawada, Y., Relationship between time after intake of grapefruit juice and the effect on the pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin. Pharmacol. Ther. 67 (2000), 201–214.
25. [25] McNeil, J.J., Drummer, O.H., Raymond, K., Conway, E.L., Louis, W.J., The influence of food on the oral bioavailability of terazosin. Br. J. Clin. Pharmacol. 32 (1991), 775–776.
26. [26] Steiner, J.F., Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin. Pharmacokinet. 30 (1996), 16–27.
27. [27] McClellan, K.J., Markham, A., Finasteride. Drugs 57 (1999), 111–126.
28. [28] Maltz, H.C., Staskin, D.R., Zoltan, E., Medication and food issues for overactive bladder/lower urinary tract symptoms: when do we eat?. Curr. Bladder Dysfunct. Rep. 4 (2009), 93–97.
29. [29] Avodart (GlaxoSmithKline): Prescribing information.